These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 23817198

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
    Christiansen MK, Jensen HK.
    Ugeskr Laeger; 2015 Mar 09; 177(11):. PubMed ID: 25786699
    [Abstract] [Full Text] [Related]

  • 5. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges.
    Norata GD, Tibolla G, Catapano AL.
    Vascul Pharmacol; 2014 Aug 09; 62(2):103-11. PubMed ID: 24924410
    [Abstract] [Full Text] [Related]

  • 6. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H, Burns TL, Hilleman DE.
    Cardiovasc Ther; 2014 Apr 09; 32(2):82-8. PubMed ID: 24354905
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A, Demir K, Altunkeser BB.
    Turk Kardiyol Dern Ars; 2014 Oct 09; 42 Suppl 2():56-67. PubMed ID: 25693363
    [Abstract] [Full Text] [Related]

  • 9. PCSK9 antibodies for the treatment of hypercholesterolemia.
    Gouni-Berthold I, Berthold HK.
    Nutrients; 2014 Dec 01; 6(12):5517-33. PubMed ID: 25470376
    [Abstract] [Full Text] [Related]

  • 10. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang E.
    Clin Pharmacol Ther; 2015 Dec 01; 98(6):590-601. PubMed ID: 26369501
    [Abstract] [Full Text] [Related]

  • 11. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I.
    Atheroscler Suppl; 2015 May 01; 18():21-7. PubMed ID: 25936300
    [Abstract] [Full Text] [Related]

  • 12. Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
    Hooper AJ, Burnett JR.
    Expert Opin Biol Ther; 2013 Mar 01; 13(3):429-35. PubMed ID: 23240807
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H, Melone M, Rashid S.
    Expert Rev Cardiovasc Ther; 2014 Oct 01; 12(10):1137-44. PubMed ID: 25244623
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PCSK9 inhibitors: an overview on a new promising lipid-lowering therapy.
    Denegri A, Petrova-Slater I, Pasotti E, Rossi MG, Pedrazzini GB, Moccetti T, Moccetti M.
    J Cardiovasc Med (Hagerstown); 2016 Apr 01; 17(4):237-44. PubMed ID: 26855411
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. PCSK9 inhibitors.
    Farnier M.
    Curr Opin Lipidol; 2013 Jun 01; 24(3):251-8. PubMed ID: 23652470
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
    Lopez D.
    Drug News Perspect; 2008 Jun 01; 21(6):323-30. PubMed ID: 18836590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.